Growth Metrics

Merck (MRK) Share-based Compensation (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -9.76%
Dec 31, 2025 0.49%
Sep 30, 2025 -5.56%
Jun 30, 2025 10.77%
Mar 31, 2025 4.28%
Dec 31, 2024 -4.10%
Sep 30, 2024 -3.94%
Jun 30, 2024 15.34%
Mar 31, 2024 5.39%
Dec 31, 2023 1.83%
Sep 30, 2023 -2.96%
Jun 30, 2023 16.55%
Mar 31, 2023 0.00%
Dec 31, 2022 4.32%
Sep 30, 2022 1.46%
Jun 30, 2022 14.17%
Mar 31, 2022 0.84%
Dec 31, 2021 1.71%
Sep 30, 2021 -11.36%
Jun 30, 2021 18.92%
Mar 31, 2021 -0.89%
Dec 31, 2020 -11.11%
Sep 30, 2020 4.13%
Jun 30, 2020 12.04%
Mar 31, 2020 31.71%
Dec 31, 2019 -18.81%
Sep 30, 2019 -9.01%
Jun 30, 2019 19.35%
Mar 31, 2019 6.90%
Dec 31, 2018 -4.40%
Sep 30, 2018 1.11%
Jun 30, 2018 12.50%
Mar 31, 2018 0.00%
Dec 31, 2017 5.26%
Sep 30, 2017 -7.32%
Jun 30, 2017 10.81%
Mar 31, 2017 -1.33%
Dec 31, 2016 -2.60%
Sep 30, 2016 -3.75%
Jun 30, 2016 17.65%
Mar 31, 2016 -12.82%
Dec 31, 2015 4.00%
Sep 30, 2015 -9.64%
Jun 30, 2015 31.75%
Mar 31, 2015 -8.70%
Dec 31, 2014 -8.00%
Sep 30, 2014 -3.85%
Jun 30, 2014 39.29%
Mar 31, 2014 -15.15%
Dec 31, 2013 -2.94%
Sep 30, 2013 -9.33%
Jun 30, 2013 11.94%
Mar 31, 2013 -14.10%
Dec 31, 2012 -11.36%
Sep 30, 2012 -5.38%
Jun 30, 2012 22.37%
Mar 31, 2012 -7.32%
Dec 31, 2011 -4.65%
Sep 30, 2011 -19.63%
Jun 30, 2011 15.05%
Mar 31, 2011 -14.68%
Dec 31, 2010 -13.49%
Sep 30, 2010 -11.27%
Jun 30, 2010 7.58%
Mar 31, 2010 -0.90%
Dec 31, 2009 57.26%
Sep 30, 2009 1.07%
Jun 30, 2009 -26.04%